Document:

EX-4.3

 Exhibit 4.3 

EXECUTION VERSION 
 REATA
PHARMACEUTICALS, INC. 
 SEVENTH AMENDED AND RESTATED 

REGISTRATION RIGHTS AGREEMENT 

This SEVENTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the
10th day of November, 2010, by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), the Investors (as defined herein), and University of Texas System (“UT System”). 

RECITALS 
 WHEREAS, on
September 27, 2002, the Company and certain other parties entered into a Registration Rights Agreement setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the
Securities Act of 1933 (the “Securities Act”); 
 WHEREAS, on September 12, 2003, the Company and certain other
parties entered into an Amended and Restated Registration Rights Agreement setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the Securities Act; 

WHEREAS, on September 22, 2004, the Company and certain other parties entered into a Second Amended and Restated Registration Rights
Agreement setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the Securities Act; 

WHEREAS, on March 8, 2006, the Company and certain other parties entered into a Third Amended and Restated Registration Rights Agreement
setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the Securities Act; 

WHEREAS, on June 12, 2007, the Company and certain other parties entered into a Fourth Amended and Restated Registration Rights Agreement
setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the Securities Act; 

WHEREAS, on November 21, 2008, the Company and certain other parties entered into a Fifth Amended and Restated Registration Rights
Agreement setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the Securities Act; 

WHEREAS, on September 15, 2009, the Company and certain other parties entered into a Sixth Amended and Restated Registration Rights
Agreement (the “Original Agreement”) setting forth their respective rights and obligations with respect to the registration of certain of the Company’s securities under the Securities Act; 

 WHEREAS, as of the date hereof, the Company is issuing 4,899,737 shares of its Series H
Preferred Stock (as defined herein) and is agreeing to issue an additional 4,899,737 shares of its Series H Preferred Stock; and 

WHEREAS, the parties hereto now desire to amend and restate the Original Agreement in its entirety as set forth herein. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby
agree as follows: 
 ARTICLE I 

CERTAIN DEFINITIONS 
 1.1
Certain Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 
 (a)
“1% Holders” shall have the meaning set forth in Section 5.7. 
 (b)
“Agreement” shall have the meaning set forth in the Preamble. 
 (c) “Board”
shall mean the Board of Directors of the Company. 
 (d) “Certificate of Incorporation” shall mean
the Ninth Amended and Restated Certificate of Incorporation of the Company filed with the Secretary of State of the State of Delaware, as amended from time to time. 

(e) “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the
time administering the Securities Act. 
 (f) “Common Stock” shall mean the Company’s common
stock, $0.001 par value per share. 
 (g) “Company” shall have the meaning set forth in the Preamble.

 (h) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar
successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(i) “Free Writing Prospectus” means any “free writing prospectus” as defined in Rule 405
promulgated under the Securities Act. 
 (j) “Holders” shall mean the Investors and UT System. 

(k) “Indemnified Party” shall have the meaning set forth in Section 5.3(c). 

(l) “Indemnifying Party” shall have the meaning set forth in Section 5.3(c). 

  
 2 

 (m) “Initiating Holders” shall mean any Holders who in
the aggregate hold more than sixty-seven percent (67%) of the outstanding Registrable Securities, on an as converted basis. 

(n) “Investor” shall mean (i) the parties to this Agreement, including the Persons listed on
Schedule A hereto, other than (A) the Company and (B) UT System, and (ii) any holder of Registrable Securities to whom the registration rights conferred by this Agreement have been transferred by an Investor in compliance with
Section 5.6 hereof. 
 (o) “Investors’ Rights Agreement” shall mean that certain
Seventh Amended and Restated Investors’ Rights Agreement, dated as of the date hereof, by and among the Company and the other parties named therein, as amended from time to time. 

(p) “Original Agreement” shall have the meaning set forth in the Recitals. 

(q) “Person” shall mean any individual, corporation, association, partnership, joint venture, trust,
limited liability company, government or government agency, authority or subdivision or other entity. 
 (r)
“Preferred Stock” shall mean the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock, the Series F Preferred Stock, the Series G1
Preferred Stock, the Series G2 Preferred Stock, the Series H Preferred Stock, and any other series of preferred stock the Company creates in the future. 

(s) “Qualified Public Offering” shall mean the closing of the sale by the Company of Common Stock in an
underwritten public offering registered under the Securities Act (other than a registration relating solely to a transaction under Rule 145 under the Securities Act (or any successor thereto) or pursuant to an employee benefit plan of the Company or
any of its subsidiaries), or any series of such sales, with aggregate gross proceeds to the Company in excess of twenty million dollars ($20,000,000) (before underwriters discounts and commissions and other expenses related to the offering have been
deducted). 
 (t) “Registrable Securities” shall mean (i) any Common Stock acquired by any
Investor or UT System, and (ii) shares of Common Stock that may be or have been acquired by any Investor or UT System pursuant to the conversion of the Preferred Stock. 

(u) The terms “register”, “registered” and
“registration” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of
the effectiveness of such registration statement. 
 (v) “Registration Expenses” shall mean all
expenses incurred in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue sky fees and
expenses, and expenses of any regular or special audits 

  
 3 

 
incident to or required by any such registration, but shall not include Selling Expenses and, except as otherwise provided herein, fees and disbursements of counsel for the Investors (and also
excluding the compensation of regular employees of the Company, which shall be paid in any event by the Company). 
 (w)
“Restricted Securities” shall have the meaning ascribed thereto in Rule 144. 
 (x) “Rule
144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(y) “Rule 145” shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such
Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 
 (z)
“Securities” means any class or series of the Company’s equity securities. 
 (aa)
“Securities Act” shall have the meaning set forth in the Recitals. 
 (bb) “Selling
Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Investor (other than the fees and disbursements of counsel for the
Company included in Registration Expenses and fees and disbursements of counsel to the Investors to be reimbursed pursuant to Section 5.1). 

(cc) “Series A Preferred Stock” shall mean the Company’s Series A Convertible Preferred Stock, par
value $0.001 per share. 
 (dd) “Series B Preferred Stock” shall mean the Company’s Series B
Convertible Preferred Stock, par value $0.001 per share. 
 (ee) “Series C Preferred Stock” shall
mean the Company’s Series C Convertible Preferred Stock, par value $0.001 per share. 
 (ff) “Series D
Preferred Stock” shall mean the Company’s Series D Convertible Preferred Stock, par value $0.001 per share. 

(gg) “Series E Preferred Stock” shall mean the Company’s Series E Convertible Preferred Stock, par
value $0.001 per share. 
 (hh) “Series F Preferred Stock” shall mean the Company’s Series F
Convertible Preferred Stock, par value $0.001 per share. 
 (ii) “Series G1 Preferred Stock” shall
mean the Company’s Series G1 Convertible Preferred Stock, par value $0.001 per share. 

  
 4 

 (jj) “Series G2 Preferred Stock” shall mean the
Company’s Series G2 Convertible Preferred Stock, par value $0.001 per share. 
 (kk) “Series H Preferred
Stock” shall mean the Company’s Series H Convertible Preferred Stock, par value $0.001 per share. 
 (ll)
“UT System” shall have the meaning set forth in the Preamble. 
 ARTICLE II 

DEMAND REGISTRATION RIGHTS 

2.1 Requested Registration of Investors and UT System. If the Company shall receive from the Initiating Holders at any time or times
after six months after the Qualified Public Offering, other than a registration relating solely to or pursuant to employee benefit plans, or a registration relating solely to a Rule 145 transaction, or a registration on any registration form under
the Securities Act that does not permit secondary sales, a written request that the Company effect any registration with respect to at least fifty percent (50%) of the Registrable Securities then outstanding and held by the Holders, or a lesser
number of Registrable Securities if the aggregate price to the public of the offering (net of any underwriter’s discounts or commissions) would be at least $5,000,000, then the Company will promptly give written notice of the proposed
registration to all other Holders and, as soon as practicable, prepare and file with the Commission such registration and use its best efforts to cause such registration to become effective (including, without limitation, filing post effective
amendments, appropriate qualifications under applicable blue sky or other state securities laws (unless, with respect to each such states’ securities laws, the Company would be required to execute a general consent to service of process in
effecting such qualification, compliance, or registration in such state, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act), and appropriate compliance with the Securities Act)
as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder joining in such request as
are specified in a written request received by the Company within twenty (20) days after delivery by the Company of such written notice. The Initiating Holders shall be entitled to specify the plan of distribution for the offering and sale of
the Registrable Securities, which plan of distribution may include an offering through one or more underwriters (who shall be selected by a majority in interest of the Initiating Holders but shall be reasonably acceptable to the Company) or a sale
of Registrable Securities in privately negotiated transactions or open market transactions through brokers, market makers or otherwise. 

2.2 Limitations and Procedures. 

(a) The Company shall not be obligated to effect, or to take any action to effect, any such registration pursuant to
Section 2.1: 
 (i) after the Company has completed two (2) registrations requested under
Section 2.1 which have been declared or ordered effective and pursuant to which Securities have been sold and registrations which have been withdrawn by the requesting parties as to which such parties have elected not to bear the

  
 5 

 
Registration Expenses pursuant to Section 5.1 hereof and would, absent such election, have been required to bear such expenses and pursuant to which the Holders are able to register
and sell a majority of the Registrable Securities requested to be included in such registration; 
 (ii) during the period of
180 days after the Qualified Public Offering (provided, however, that during such 180 day period the Company shall be obligated to commence preparation of the registration statement in good faith and take all other actions specified
herein in anticipation of the offering and sale of the Registrable Securities but shall not be obligated to file such registration statement with the Commission until immediately following the expiration of such period); or 

(iii) if the Company furnishes to the Initiating Holders a certificate signed by an officer of the Company stating that, in the
good faith judgment of a majority of the Board, it would be seriously detrimental to the Company and its stockholders for such registration to be effected at such time, the Company shall have the right to defer the filing of the registration
statement for a period of not more than one hundred eighty (180) days after receipt of the request of the Initiating Holders under Section 2.1; provided, however, that the Company shall not utilize this right more than
once in any twelve (12) month period. 
 (b) Subject to Section 2.2(a), the Company shall file a
registration statement covering the Registrable Securities so requested to be registered as soon as practicable after (but in no event more than 90 days after) receipt of the request or requests of the Initiating Holders. 

(c) Any registration statement filed pursuant to request under Section 2.1 may, subject to Section 5.8
hereof, include other Securities of the Company in such registration unless the Initiating Holders and, if the Initiating Holders have engaged an underwriter, the underwriter notify the Company that they have determined that the inclusion of such
Securities would be likely to have a material adverse effect on the offering and sale by them of the Registrable Securities. 

(d) In the case of an underwritten offering, the right of any participant to registration pursuant to Section 2.1
shall be conditioned upon such participant’s participation in such underwriting and the inclusion of such participant’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the other
participants therein and such participant with respect to such participation and inclusion) to the extent provided herein. Subject to Section 5.8, a Holder may elect to include in such underwriting all or a part of the Registrable
Securities such Holder holds. 
 (e) In the case of an underwritten offering, the Company shall (together with all Persons
proposing to distribute their Securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision
of 

  
 6 

 
this Article II, if the representative of the underwriters advises the Initiating Holders in writing that for any reason a limitation on the number of shares to be underwritten is
required, the number of shares to be included in the underwriting or registration shall be allocated as set forth in Section 5.8 hereof. 

ARTICLE III 

REGISTRATION BY COMPANY 

3.1 Company Registration. If at any time after a Qualified Public Offering, the Company shall determine to register any of its
Securities either for its own account or the account of a security holder or holders, other than a registration relating solely to or pursuant to employee benefit plans, or a registration relating solely to a Rule 145 transaction, or a registration
on any registration form under the Securities Act that does not permit secondary sales, the Company will: 
 (a) promptly
give to each Holder written notice thereof; and 
 (b) include in such registration (and any related qualification under blue
sky laws or other compliance), except as set forth in Section 3.2 below, and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made by any Holder and received by the Company
within thirty (30) days after the written notice from the Company described in clause (a) above is delivered by the Company. Such written request may specify all or a part of a Holder’s Registrable Securities. 

3.2 Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an underwriting,
the Company shall so advise the Holders as a part of the written notice given pursuant to Section 3.1(a). In such event, the right of any Holder to registration pursuant to this Article III shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein and in Section 5.8. All Holders proposing to distribute any Securities
through such underwriting shall (together with the Company) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected by the Company. 

ARTICLE IV 
 FORM S-3
REGISTRATION 
 4.1 S-3 Registration. In case the Company shall receive from Initiating Holders a written request or requests
that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Initiating Holders, the Company will: 

(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other
Holders; and 
 (b) as soon as practicable, effect such registration and all such qualifications and compliances as may be so
requested and as would permit or facilitate the sale and 

  
 7 

 
distribution of all or such portion of such Initiating Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of
any other Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to
effect any such registration, qualification or compliance, pursuant to this Article IV: 
 (i) if Form S-3 is not
available for such offering by the Initiating Holders; or 
 (ii) if the Initiating Holders, together with the holders of any
other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $1,000,000. 

4.2 Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so
requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders. Registrations effected pursuant to this Article IV shall not be counted as demands for registration or registrations
effected pursuant to Articles II or III, respectively. 
 ARTICLE V 

EXPENSES, INDEMNIFICATION AND CERTAIN MECHANICS 

5.1 Expenses of Registration. All (a) Registration Expenses incurred in connection with (i) any registration, qualification
or compliance pursuant to Section 3.1 hereof, (ii) any registration pursuant to Section 2.1, (iii) up to four (4) registrations pursuant to Section 4.1 and (iv) any registration initiated
pursuant to the terms of Section 2.1 in which the Holders are permitted, pursuant to the terms of Section 5.8, to register less than the number of shares such Holders request to include and such Holders continue to
participate in the registered offering, and (b) reasonable fees of one counsel for the Holders for any registration effected pursuant to Section 2.1 or Section 3.1 and for up to four (4) registrations effected
pursuant to Section 4.1 shall be borne by the Company subject to the provisions contained in the next sentence. Any Registration Expenses for any other offering shall be borne pro rata among all of the selling stockholders. If the
Holders bear the Registration Expenses for any registration proceeding begun pursuant to Section 2.1 and subsequently withdrawn by the Holders registering shares therein, such registration proceeding shall not be counted as a requested
registration pursuant to Section 2.1. If the Holders do not bear the Registration Expenses for any registration proceeding begun pursuant to Section 2.1 and subsequently withdrawn by such Holders registering shares therein,
such registration proceeding shall be counted as a requested registration pursuant to Section 2.1 unless such withdrawal is based upon material adverse information relating to the Company which differs from information publicly available
at the time of their request for registration under Section 2.1. All Selling Expenses relating to Securities so registered shall be borne by the holders of such Securities. 

  
 8 

 5.2 Registration Procedures. In the case of each registration effected by the Company
pursuant to this Agreement, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will: 

(a) prepare and file with the Commission a registration statement with respect to the Registrable Securities and use its best
efforts to cause such registration statement to become effective, and keep such registration effective for a period of one hundred eighty (180) days or until the Holders have completed the distribution described in the registration statement
relating thereto, whichever first occurs; provided, however, that such one hundred eighty (180) day period shall be extended for a period of time equal to the period the Holders refrain from selling any Securities included in such
registration at the request of the Company or an underwriter of Common Stock (or other Securities) of the Company; and in the case of any registration of Registrable Securities on Form S-3 which is intended to be offered on a continuous or delayed
basis, such 180-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a
continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (i) includes any prospectus
required by Section 10(a)(3) of the Securities Act or (ii) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information
required to be included in (i) and (ii) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement; 

(b) prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used
in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all Securities covered by such registration statement; 

(c) furnish such number of prospectuses and other documents incident thereto, including any amendment of or supplement to the
prospectus and any Free Writing Prospectus used in connection therewith, as a Holder from time to time may reasonably request; 

(d) notify each holder of Registrable Securities covered by such registration statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing, and prepare and furnish to each Holder a reasonable number of copies of a
supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing; 

  
 9 

 (e) cause all such Registrable Securities registered pursuant hereunder to be
listed on each securities exchange on which similar securities issued by the Company are then listed; 
 (f) provide a
transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(g) in connection with any underwritten offering, the Company will enter into an underwriting agreement reasonably necessary to
effect the offer and sale of Common Stock, provided such underwriting agreement contains customary underwriting provisions; 

(h) take all reasonable actions to ensure that any Free Writing Prospectus utilized in connection with any registration
hereunder complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby and, when taken
together with the related prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; 

(i) register or qualify the Registrable Securities covered by such registration statement under the securities or blue sky laws
of such jurisdictions as the Investors shall reasonably request, keep such registration or qualification in effect for so long as such registration statement remains in effect and do any and all other acts and things which may be reasonably
necessary or appropriate to enable the Investors to dispose of the Registrable Securities in such jurisdiction; 
 (j) notify
each Holder promptly (i) when such registration statement and any post-effective amendment thereto has become effective under the Securities Act, (ii) of any request by the Commission for an amendment or supplement to such registration
statement or the prospectus included therein or for additional information, (iii) of the issuance by the Commission of any stop order suspending the effectiveness of such registration statement or the initiation of any proceedings for that
purpose and (iv) of the receipt of any notification with respect to the suspension of the registration or qualification of any Registrable Securities in any jurisdiction in which they are registered or qualified or the initiation of any
proceedings for that purpose; 
 (k) use commercially reasonable efforts to obtain the withdrawal at the earliest possible
moment to any stop order suspending the effectiveness of such registration statement and the lifting at the earliest possible moment of any suspension of the registration or qualification of the Registrable Securities in any jurisdiction in which
they are registered or qualified; 

  
 10 

 (l) otherwise use its best efforts to comply with all applicable rules and
regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering a period of twelve (12) months after the effective date of such registration statement, which earnings
statement shall satisfy the provisions of Section 11(a) of the Securities Act; 
 (m) furnish, at the request of any
Holder requesting registration of Registrable Securities, on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, or, if such securities are not being sold
through underwriters, on the date that the registration statement with respect to such securities becomes effective, (1) a copy of the opinion, if any, of the counsel representing the Company for the purposes of such registration that has been
delivered to the underwriters in an underwritten public offering, provided that such counsel shall permit the Holders to rely on such opinion, and (2) the “comfort” letter, if any, dated as of such date, from the independent certified
public accountants of the Company, which must also be addressed to the Holders; 
 (n) make available for inspection by any
underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant, or other agent retained by any such underwriter, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such underwriter, attorney, accountant, or agent in connection with such registration statement;

 (o) permit any holder of Registrable Securities that might be deemed, in the sole and exclusive judgment of the holder
thereof, to be an underwriter or a controlling person of the Company, to participate in the preparation of such registration or comparable statement and to require the insertion in such registration or comparable statement of material, furnished to
the Company in writing, that in the reasonable judgment of such holder and his, her, or its counsel should be included; and 

(p) if any such registration or comparable statement refers to any holder by name or otherwise as the holder of any Securities
and if, in the sole and exclusive judgment of such holder, such holder is or might be deemed to be a controlling person of the Company, such holder shall have the right to require (1) the inclusion in such registration statement of language, in
form and substance reasonably satisfactory to such holder, to the effect that the holding of such Securities by such holder is not to be construed as a recommendation by such holder of the investment quality of the Securities covered by such
registration statement and that such holding does not imply that such holder shall assist in meeting any future financial requirements of the Company or (2) in the event that such reference to such holder by name or otherwise is not required by
the Securities Act or any similar federal statute then in force, the deletion of the reference to such holder; provided that with respect to this clause (2) such holder shall furnish to the Company an opinion of counsel to such effect, which
opinion of counsel shall be reasonably satisfactory to the Company. 

  
 11 

 5.3 Indemnification. 

(a) The Company will indemnify and hold harmless each Holder, each of its employees, officers, directors and partners, legal
counsel, and accountants and each person controlling such Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, with respect to which registration, qualification, or compliance has been effected
pursuant to this Agreement, and each underwriter, if any, and each person who controls within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act any underwriter, against all expenses, claims, losses, damages,
and liabilities (or actions, proceedings, or settlements in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus, Free Writing Prospectus, offering circular, or
other document (including any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, or any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation thereunder applicable to the
Company and relating to action or inaction required of the Company in connection with any such registration, qualification, or compliance, and will reimburse each such Holder and each of its employees, officers, directors, partners, legal counsel,
and accountants and each person controlling such Holder, each such underwriter, and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling
any such claim, loss, damage, liability, or action; provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or expense arises out of or is based on any untrue statement or omission
based upon written information furnished to the Company by such Holder in its capacity as a Holder, and not in their capacity as a director, officer or employee of the Company, if applicable, or underwriter and stated to be specifically for use
therein. It is agreed that the indemnity agreement contained in this Section 5.3(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of
the Company (which consent shall not have been unreasonably withheld). 
 (b) Each Holder will, if Securities held by such
Holder are included in the Securities as to which such registration, qualification, or compliance is being effected, severally and not jointly, indemnify the Company, each of its directors, officers, employees, partners, legal counsel, and
accountants and each underwriter, if any, of the Securities covered by such registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other Holder, and each of
their officers, directors, and partners, and each person controlling such other Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement)
of a material fact contained in any such registration statement, prospectus, Free Writing Prospectus, offering circular, or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the Company and such other 

  
 12 

 
Holders, directors, officers, partners, legal counsel, and accountants, persons, underwriters, or control persons for any legal and any other expenses reasonably incurred in connection with
investigating or defending any such claim, loss, damage, liability, or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such
registration statement, prospectus, Free Writing Prospectus, offering circular, or other document in reliance upon and in conformity with written information furnished to the Company by such Holder in its capacity as a Holder, and not in its
capacity as a director, officer or employee of the Company, if applicable, and stated to be specifically for use therein. It is agreed that the indemnity agreement contained in this Section 5.3(b) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Holder (which consent shall not have been unreasonably withheld). In no event shall any indemnity under this
Section 5.3(b) exceed the net proceeds from the offering received by such Holder. 
 (c) Each party entitled to
indemnification under this Section 5.3 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such
Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense, but
the fees and expenses of such counsel shall be at the expense of the Indemnified Party unless (i) the Indemnifying Party has agreed in writing to pay such fees and expenses or (ii) the named parties to any such action or proceeding
(including any impleaded parties) include both the Indemnified Party and the Indemnifying Party, and the Indemnified Party shall have been advised by counsel that there may be one or more legal defenses available to such Indemnifying Party which are
different from or additional to those available to the Indemnified Party (in which case, if the Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the
Indemnifying Party shall not have the right to assume the defense of such action or proceeding on behalf of the Indemnified Party). The failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of
its obligations under this Agreement, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or
enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall
furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 

(d) If the indemnification provided for in this Section 5.3 is held by a court of competent jurisdiction to be
unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to therein, then the Indemnifying Party, in 

  
 13 

 
lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in
such proportion as is appropriate to reflect the relative fault of the Indemnifying Party, on the one hand, and of the Indemnified Party, on the other hand, in connection with the statements or omissions that resulted in such loss, liability, claim,
damage, or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to
correct or prevent such statement or omission. 
 (e) The obligations of the Company and the Holders under this
Section 5.3 shall survive the completion of any offering of Registrable Securities in a registration statement and shall survive the termination of this Agreement. 

5.4 Information by Holders. Each Holder shall furnish to the Company such information regarding such Holder and the distribution
proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this Agreement. 

5.5 Rule 144 Reporting. The Company covenants that, from and after the closing of a public offering of equity securities pursuant to an
effective registration statement under the Securities Act, it shall file any reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations thereunder, and it shall take such further action, that any
Holder may reasonably request to enable such Holder to sell Restricted Securities, from time to time, without registration under the Securities Act within the limitation of the exemptions provided by Rule 144. Upon the request of any Holder, the
Company shall deliver to such Holder a written statement as to whether it has complied with such information and requirements. 
 5.6
Transfer or Assignment of Registration Rights. The rights to cause the Company to register Securities granted to a Holder by the Company under this Agreement may be transferred or assigned by a Holder in connection with any transfer of the
Registrable Securities or Securities which may be exercised for or converted into Registrable Securities provided that (a) the Company is given written notice of such transfer or assignment, stating the name and address of the transferee or
assignee and identifying the Registrable Securities or Securities which may be exercised for or converted into Registrable Securities with respect to which such registration rights are being transferred or assigned, (b) the transferee or
assignee (i) acquires at least 166,666 shares of the Preferred Stock originally owned by the transferring Holder, (ii) acquires, if less than 166,666 shares of Preferred Stock, all shares of Preferred Stock held by such Holder if
transferred to a single entity or (iii) is a partner of either Ojai Goliad Partners, LP, Ojai Goliad Partners II, LP or Redbird Life Sciences Partners, L.P., and acquires the Preferred Stock as a distribution from such partnership, (c) the
transferee or assignee of such rights assumes the obligations of such Holder under this Agreement and (d) such Holder complies with any other applicable restrictions on transfers under the Investors’ Rights Agreement. 

  
 14 

 5.7 “Market Stand-Off” Agreement. If requested by the Company and an underwriter
of Common Stock (or other Securities) of the Company in a Qualified Public Offering, a Holder shall not sell or otherwise transfer or dispose of any Common Stock (or other Securities) of the Company held by such Holder (other than those included in
the registration) during the period requested by the representative of the underwriters, which shall not exceed a one hundred eighty (180) day period (or such lesser time as may be agreed upon by the Company and its underwriter) following the
effective date of a registration statement of the Company filed under the Securities Act; provided, however, that (i) such Market Stand-Off Agreement shall be applicable only if all directors, officers and holders of at least 1%
of the outstanding Common Stock (on an as-converted basis) (“1% Holders”) enter into similar agreements, and (ii) in no event shall such holdback period be longer than the period that officers, directors and 1% Holders
agree to be subject to such restraints. The obligations described in this Section 5.7 shall not apply to a registration relating solely to employee benefit plans on Form S-8 or similar forms that may be promulgated in the future, or a
registration relating solely to a Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the Common Stock (or other Securities) subject to the
foregoing restriction until the end of such one hundred eighty (180) day period. 
 5.8 Allocation of Registration
Opportunities. In any registration the subject of this Agreement where any Person with registration rights requests inclusion of Registrable Securities therein and not all of such Registrable Securities can be so included as a result of
limitations as determined pursuant to this Agreement, the number of shares of Registrable Securities to be registered for the account of the Company, and Registrable Securities of other Persons that may be so included, shall be allocated among the
Company and Persons requesting inclusion of shares as follows: 
 (a) In any registration pursuant to Section 2.1
or Section 4.1, (i) first, to the Holders holding shares of Common Stock issued or issuable upon conversion of the Preferred Stock requesting inclusion in such registration on a pro rata basis until such Holders have included all of
the Registrable Securities that such Holders requested to include in such registration, (ii) second, to the Holders holding shares of Common Stock (other than those shares of Common Stock described in clause (i) above) requesting inclusion
in such registration on a pro rata basis until such Holders have included all of the Registrable Securities that such Holders requested to included in such registration and (iii) to other Persons participating in such registration pro rata on
the basis of the number of Registrable Securities that such other Persons requested to include in such registration. 
 (b)
In any registration other than pursuant to Section 2.1 and Section 4.1, (i) first, to the Company until the Company has included all of the Registrable Securities that the Company desires to include in such registration,
(ii) second, to the Holders holding shares of Common Stock issued or issuable upon conversion of the Preferred Stock requesting inclusion in such registration on a pro rata basis until such Holders have included all of the Registrable
Securities that such Holders requested to include in such registration, (iii) third, to the Holders holding shares of Common Stock (other than those shares of Common Stock described in clause (ii) above) requesting inclusion in such
registration on a pro rata basis until such Holders have included all of the Registrable Securities that such Holders requested to included in such registration and (iv) to other 

  
 15 

 
Persons participating in such registration pro rata on the basis of the number of Registrable Securities that such other Persons requested to include in such registration; provided that,
in no event shall the amount of securities of the selling Holders included in an offering be reduced unless securities of all other selling stockholders are excluded entirely and then such amount shall not be reduced below 25% of the total amount of
Securities included in the offering. 
 (c) If any Holder does not request inclusion of the maximum number of shares of
Registrable Securities allocated to such Holder pursuant to the above described procedure, such allocation shall not operate to reduce the aggregate number of Registrable Securities to be included in such registration and the remaining portion of
such Holder’s allocation shall be reallocated among those requesting Holders whose allocations did not satisfy their requests in accordance with the priorities set forth in Sections 5.8(a) and (b) pro rata on the basis of the
number of shares of Registrable Securities which would be held by such Holders, and this procedure shall be repeated until all of the shares of Registrable Securities which may be included in the registration on behalf of the Holders have been so
allocated. 
 (d) The Company shall not limit the number of Registrable Securities to be included in a registration pursuant
to this Agreement in order to include Registrable Securities held by Persons other than the Holders or the Company. 
 (e)
Each of the provisions of this Section 5.8 which refers to Registrable Securities assumes full conversion of Preferred Stock. 

ARTICLE VI 

MISCELLANEOUS 
 6.1
Termination. This Agreement shall terminate with respect to any Holder, upon such Holder’s ability to sell, within any ninety (90) day period, all of its Registrable Securities without registration in compliance with Rule 144 of the
Securities Act. 
 6.2 Additional Investors. Anything in this Agreement to the contrary notwithstanding, from time to time additional
Persons may become “Investors” under this Agreement, without the consent of any Holder, upon the execution by the Company and such Person of a supplement to this Agreement in substantially the same form as Exhibit A attached hereto
(each, a “Supplement”). 
 6.3 Additional Registration Rights. The Company shall not grant to any third party
any registration rights that are pari passu or more favorable than those contained herein with respect to priority of registration, so long as any of the registration rights under this Agreement remain in effect, without the consent required by
Section 6.6 of this Agreement. 
 6.4 Governing Law. This Agreement shall be governed in all respects by the laws of the
State of Texas, as if entered into by and between Texas residents exclusively for performance entirely within Texas. 

  
 16 

 6.5 Successors and Assigns. All covenants and agreements contained in this Agreement by or
on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors, assigns, heirs, executors and administrators of the Company and each of the Holders (including without limitation transferees of any Registrable
Securities or Securities which may be exercised or converted into Registrable Securities), whether so expressed or not, provided, however, that the registration rights conferred in this Agreement on the holders of such Registrable
Securities or Securities which may be exercised or converted into Registrable Securities shall only inure to the benefit of a transferee of such Registrable Securities or Securities which may be exercised or converted into Registrable Securities if
such transferee acquires the Registrable Securities or Securities which may be exercised or converted into Registrable Securities in accordance with Section 5.6 of this Agreement. 

6.6 Entire Agreement; Amendment; Waiver. This Agreement constitutes the full and entire understanding and agreement among the parties
with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated, except by a written instrument signed by the Company and the holders of at least a majority of the then
outstanding Preferred Stock and Common Stock issued upon conversion thereof voting together as a single class and calculated on an as-converted basis and any such amendment, waiver, discharge or termination shall be binding on the Company and all
the Holders and their assignees, but in no event shall the obligations of any Holder hereunder be materially increased, except upon the written consent of such Holder. 

6.7 Notices, etc. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by
United States first class mail, postage prepaid, or delivered personally by hand or nationally recognized courier addressed (a) if to a Holder, as indicated on the signature pages hereof, or at such other address as such holder or permitted
assignee shall have furnished to the Company in writing, or (b) if to the Company, at its executive offices, or at such other address as the Company shall have furnished to each stockholder in writing. All such notices and other written
communications shall be effective (i) if mailed, three (3) days after mailing and (ii) if delivered by hand or courier, upon delivery. 

6.8 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party hereto, upon any breach or
default of any other party hereto shall impair any such right, power or remedy of such non breaching or defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar
breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the
part of any party hereto of any breach or default under this Agreement or any waiver on the part of any party hereto of any provisions or conditions of this Agreement must be made in writing executed by such party and shall be effective only to the
extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party hereto, shall be cumulative and not alternative. 

6.9 Rights; Separability. Unless otherwise expressly provided herein, a party’s rights hereunder are several rights, not rights
jointly held with any of the other parties. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired
thereby. 

  
 17 

 6.10 Titles and Subtitles. The titles of the paragraphs and subparagraphs of this
Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 
 6.11 Counterparts. This
Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 

[Remainder of Page Intentionally Left Blank] 

  
 18 

 IN WITNESS WHEREOF, the Company has executed this Seventh Amended and Restated Registration
Rights Agreement effective as of the day and year first above written. 
  

			
	THE COMPANY:
	
	REATA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ J. Warren Huff

		 	J. Warren Huff
		 	Chief Executive Officer
		
	Address:	 	2801 Gateway Drive, Suite 150
		 	Irving, Texas 75063-2648
	Fax:	 	(214) 722-0867

  
 19 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	STARTECH SEED FUND II, LP
		
	By:	 	STARTech Associates II, LP,
		 	its General Partner
		
	By:	 	STARTech Equity II, LLC,
		 	its General Partner
		
	By:	 	 /s/ Matthew S. Blanton

	Name:	 	Matthew S. Blanton
	Title:	 	Managing Member
		
	Address:	 	1302 E. Collins Blvd.
		 	Richardson, Texas 75083
	Fax:	 	(214) 576-9849

  
 20 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	MATTHEW S. BLANTON, LTD.
		
	By:	 	 /s/ Matthew S. Blanton

	Name:	 	Matthew S. Blanton
	Title:	 	General Partner
		
	Address:	 	2400 W. Harris Road
		 	Arlington, Texas 76001
	Fax:	 	(214) 576-9849

  
 21 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	RWI PARTNERSHIP, LTD.
		
	By:	 	 /s/ Risher Randall

	Name:	 	Risher Randall
	Title:	 	Partner
		
	Address:	 	2001 Kirby Drive, Suite 610
		 	Houston, Texas 77019
	Fax:	 	(713) 523-6605

  
 22 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	 /s/ Elizabeth T.S. Joyce

	Name:	 	Elizabeth T.S. Joyce
		
	Address:	 	157 Bridle Trail Road
		 	                                , MA 02492
	Fax:	 	(781) 444-7494

  
 23 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	 /s/ Charles A. Sanders

	Name:	 	Charles A. Sanders, M.D.
		
	Address:	 	3200 Rugby Road
		 	Durham, North Carolina 27707
	Fax:	 	919-932-7588

  
 24 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	WF9 INVESTMENTS L.P.
		
	By:	 	Walter Brothers,
		 	its General Partner
		
	By:	 	 /s/ Jeffrey J. Walter

	Name:	 	Jeffrey J. Walter
	Title:	 	Managing Agent
		
	Address:	 	3701 Centenary Drive
		 	Dallas, Texas 75225
	Fax:	 	(214) 369-1462

  
 25 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	NOVO A/S
		
	By:	 	 /s/ Soren Carlsen

	Name:	 	Soren Carlsen
	Title:	 	Managing Partner
		
	Address:	 	Novo A/S
		 	Tuborg Havnevej 19
		 	DK-2900 Hellerup
		 	Denmark

  
 26 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	 /s/ Freddie Carroll

	Name:	 	Freddie Carroll
		
	Address:	 	3305 Twin Diamond Ct.
		 	Plano, Texas 75023
	Fax:	 	972-883-4919

  
 27 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	CARDINAL PARTNERS 2000, LP
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	(214) 871-6837

  
 28 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	YELLOW WARBLER, LP
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	(214) 871-6837

  
 29 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	CARDINAL PARTNERS, L.P.
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	(214) 871-6837

  
 30 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	CD FUND, LP
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	214-871-6837

  
 31 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	ARACOS FUND, L.P.
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	(214) 871-6837

  
 32 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	MALLARD FUND, LP
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	214-871-6837

  
 33 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	REDBIRD LIFE SCIENCES PARTNERS, L.P.
		
	By:	 	Redbird Life Sciences, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John E. Bateman

	Name:	 	John E. Bateman
	Title:	 	President
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	(214) 871-6837

  
 34 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	VERDIN FUND, LP
		
	By:	 	CPMG, Inc.,
		 	its General Partner
		
	By:	 	 /s/ John Bateman

	Name:	 	John Bateman
	Title:	 	Chief Operating Officer
		
	Address:	 	2100 McKinney, Suite 1770
		 	Dallas, Texas 75201
	Fax:	 	(214) 871-6837

  
 35 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	 /s/ Peter P. Smith

	Name:	 	Peter P. Smith
	
	 /s/ Bonnie B. Smith

	Name:	 	Bonnie B. Smith
		
	Address:	 	1901 N. Akard St.
		 	Dallas, TX 75201
	Fax:	 	(214) 720-9144

  
 36 

 IN WITNESS WHEREOF, UT System has executed this Seventh Amended and Restated Registration Rights
Agreement effective as of the day and year first above written. 
  

			
	UNIVERSITY OF TEXAS SYSTEM
		
	By:	 	 /s/ John A. Roan

	Name:	 	John A. Roan
	Title:	 	Executive Vice President for Business Affairs
		
	Address:	 	5323 Harry Hines Blvd.
		 	UT Southwestern
		 	Dallas, Texas 75390 8596
	Fax:	 	214-648-3944

  
 37 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	OJAI GOLIAD PARTNERS, LP
		
	By:	 	Ojai Goliad, LLC
		 	its General Partner
		
	By:	 	 /s/ James E. Bass

	Name:	 	James E. Bass
	Title:	 	Manager
		
	Address:	 	2626 Cole Avenue, Suite 400
		 	Dallas, Texas 75204
	Fax:	 	(214) 237-0338

  
 38 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	LONESTAR SERVICES LIMITED
		
	By:	 	 /s/ James Bass

	Name:	 	James Bass
	Title:	 	President
		
	Address:	 	5375 Waneta Drive
		 	Dallas, Texas 75209
	Fax:	 	(214) 237-0338

  
 39 

 IN WITNESS WHEREOF, UT System has executed this Seventh Amended and Restated Registration Rights
Agreement effective as of the day and year first above written. 
  

			
	 /s/ James Bass

	Name:	 	James Bass
		
	Address:	 	2626 Cole Avenue, Suite 400
		 	Dallas, Texas 75204
	Fax:	 	214-237-0338

  
 40 

 IN WITNESS WHEREOF, UT System has executed this Seventh Amended and Restated Registration Rights
Agreement effective as of the day and year first above written. 
  

			
	 /s/ James E. Bass

	Name:	 	James E. Bass
	
	 /s/ Hong Z. Bass

	Name:	 	Hong Z. Bass
		
	Address:	 	2626 Cole Ave., Suite 400
		 	Dallas, TX 75204
	Fax:	 	(214) 237-0338

  
 41 

 IN WITNESS WHEREOF, UT System has executed this Seventh Amended and Restated Registration Rights
Agreement effective as of the day and year first above written. 
  

			
	OJAI GOLIAD PARTNERS II, LP
		
	By:	 	Ojai Goliad, LLC
		 	its General Partner
		
	By:	 	 /s/ James E. Bass

	Name:	 	James Bass
	Title:	 	Manager
		
	Address:	 	2626 Cole Avenue, Suite 400
		 	Dallas, Texas 75204
	Fax:	 	(214) 237-0338

  
 42 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	LYDA HILL INTERESTS, INC.
		
	By:	 	 /s/ Frank Mackey

	Name:	 	Frank Mackey
	Title:	 	Vice President
		
	Address:	 	1601 Elm Street, Suite 5000
		 	Dallas, Texas 75201
	Fax:	 	(214) 922-1048

  
 43 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	CHATHAM HILL INVESTMENT
	PARTNERSHIP, LTD.
		
	By:	 	 /s/ Chatham Hill Investment Partnership,
S. Roder Horchow

	Name:	 	S. Roder Horchow
	Title:	 	Gen Partner
		
	Address:	 	5722 Chatham Hill Road
		 	Dallas, Texas 75225
	Fax:	 	(214) 692-6014

  
 44 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Seventh Amended and Restated
Registration Rights Agreement effective as of the day and year first above written. 
  

			
	  

	[Please print name of Investor]
		
	By:	 	  

	Name:	 	  

	Title:	 	  

		
	Address:	 	  

		 	  

	Fax:	 	  

  
 45 

 SCHEDULE A 

INVESTORS 
  

	1.	Ojai Goliad Partners, LP 

  

	2.	STARTech Seed Fund II, L.P. 

  

	3.	Anchor International Services Limited 

  

	4.	The Lyda Hill Foundation 

  

	5.	ILC Realty Ltd. 

  

	6.	Bruce W. Hunt 

  

	7.	Barbara Hunt Crow 

  

	8.	Kingdom Investments, Limited 

  

	9.	Hunt Technology Ventures, LP 

  

	10.	Peter Moody Brooks 

  

	11.	Lonestar Services Limited 

  

	12.	Ojai Goliad Partners II, LP 

  

	13.	James F. Watson 

  

	14.	WF9 Investments L.P. 

  

	15.	Redbird Life Sciences Partners, L.P. 

  

	16.	Dennis J. Gorman 

  

	17.	Peachway, LLC 

  

	18.	Freddie Carroll 

  

	19.	Ronald B. Jennings 

  

	20.	RWI Partnership, Ltd. 

  

	21.	James E. and Hong Z. Bass 

  

	22.	Prothro Family Limited Partnership, Ltd. 

  

	23.	Peter P. and Bonnie B. Smith 

  

	24.	Charles A. Sanders, M.D. 

  

	25.	Leslie Clement Family Trust 

  

	26.	Alice Carrington Foultz 

  

	27.	The Henrietta P.C. Hildebrand Trust of 2007 

  

	28.	Martin W. Clement II 

  

	29.	Scott Dodds 

  

	30.	Chatham Hill Investment Partnership, Ltd. 

  
 Schedule A - 1 

	31.	Kingdon R. Hughes 

  

	32.	Cardinal Partners, L.P. 

  

	33.	John P. Watters 

  

	34.	Clement Equities 

  

	35.	Novo A/S 

  

	36.	James W. Lewis MPPP 

  

	37.	James W. Lewis IRA 

  

	38.	James W. Lewis Family Investment Limited Partners 

  

	39.	James W. Lewis 

  

	40.	Colin J. Meyer, M.D. 

  

	41.	John Walling 

  

	42.	Melissa Krauth 

  

	43.	Ron Bumeister 

  

	44.	Glenda Johnson 

  

	45.	Robert M. Kral, Jr. 

  

	46.	Christiane Baud 

  

	47.	Christina Adams 

  

	48.	Karen Rohan 

  

	49.	Angela Dunford 

  

	50.	Pritam Kambuj 

  

	51.	Aracos Fund, L.P. 

  

	52.	James E. Bass 

  

	53.	Matthew S. Blanton, Ltd. 

  

	54.	Cardinal Partners 2000, LP 

  

	55.	CD Fund, LP 

  

	56.	Bradford H. Hughes 

  

	57.	Mi-Hyung Kim 

  

	58.	Lyda Hill Interests, Inc. 

  

	59.	Mallard Fund, LP 

  

	60.	Barbara B. Moroney 

  

	61.	Yellow Warbler, LP 

  

	62.	Henrietta PC Hildebrand 

  
 Schedule A - 2 

	63.	Oxford Finance Corporation 

  

	64.	Sumitomo Corporation of America 

  

	65.	Sumitomo Corporation 

  

	66.	Numoda Capital Innovations LLC 

  

	67.	Verdin Fund, LP 

  

	68.	Whitney R. Hughes 

  

	69.	Elizabeth T.S. Joyce 

  

	70.	Gorman Children’s Trust I 

  

	71.	Gorman Children’s Trust II 

  

	72.	Abbott Pharmaceuticals PR Ltd. 

  

	73.	J. Warren Huff 

  
 Schedule A - 3 

 EXHIBIT A 

SUPPLEMENT TO REGISTRATION RIGHTS AGREEMENT 

This Supplement (this “Supplement”) to the Seventh Amended and Restated Registration Rights Agreement (the
“Registration Rights Agreement”) dated as of November 10, 2010, by and among Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Investors (as defined therein) and University of Texas
System, is entered into as of             , 20    , between
                     (the “New Investor”), and the Company, pursuant to the terms of the Registration Rights Agreement. 

Agreements 

For valuable consideration, whose receipt and sufficiency are hereby acknowledged, New Investor is added as an
“Investor” under the Registration Rights Agreement and New Investor hereby agrees that it shall be bound by the terms thereof. 

Executed as of the date first written above. 

 

			
	 NEW INVESTOR:

	
	  

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

		
	 Address:
	 	
	
	  

	  

	 Fax:
	 	  

	
	 REATA PHARMACEUTICALS, INC.

		
	 By:
	 	  

	 Name:
	 	  

	 Title:EX-10.1

 Exhibit 10.1 

REATA PHARMACEUTICALS, INC. 

INDEMNIFICATION AGREEMENT 

This Agreement (“Agreement”) is made and entered into as of the 23rd day of September, 2015, by and between Reata Pharmaceuticals, a
Delaware corporation (the “Company”), and J. Warren Huff (“Indemnitee”). 
 RECITALS 

A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in other capacities
unless they are provided with adequate protection through insurance and indemnification against claims and actions against them arising out of their service to and activities on behalf of the Company. 

B. The Board of Directors of the Company (the “Board”) has determined that the inability to attract and retain such persons
would be detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future. 

C. The Board has also determined that it is reasonable, prudent and necessary for the Company, in addition to purchasing and maintaining
directors’ and officers’ liability insurance (or otherwise providing for adequate arrangements of self-insurance), contractually to obligate itself to indemnify such persons to the fullest extent permitted by applicable law so that they
will serve or continue to serve the Company free from undue concern that they will not be adequately protected. 
 D. Indemnitee is
willing to serve, continue to serve and to take on additional service for or on behalf of the Company, but only on the condition that Indemnitee be so indemnified to the fullest extent permitted by law, as permitted herein. 

E. Article Thirteen of the Amended and Restated Certificate of Incorporation of the Company provides for indemnification of directors and
officers to the fullest extent permitted by law. 

  
 1 

 In consideration of the foregoing and the mutual covenants herein contained, and other good and
valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE I

 Certain Definitions 

As used herein, the following words and terms shall have the following respective meanings (whether singular or plural): 

“Acquiring Person” means any Person other than (i) the Company, (ii) any of the Company’s Subsidiaries,
(iii) any employee benefit plan of the Company or of a Subsidiary of the Company or of a Company owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company,
or (iv) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary of the Company or of a Company owned directly or indirectly by the stockholders of the Company in substantially the same
proportions as their ownership of stock of the Company. 
 “Change in Control” means the occurrence of any of the following
events: 
 (i) The acquisition, after the date of this Agreement, by any Person of beneficial ownership (within the meaning of Rule
13d-3 promulgated under the Exchange Act) of 40% or more of either (x) the then outstanding shares of Common Stock of the Company (the “Outstanding Company Common Stock”) or (y) the combined voting power of the then outstanding
voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this Subparagraph (i), the following acquisitions shall not
constitute a Change of Control: (A) any acquisition directly from the Company, (B) any acquisition by the Company, (C) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any
corporation controlled by the Company or (D) any acquisition by any corporation pursuant to a transaction which complies with clauses (A), (B) and (C) of paragraph (iii) below; or 

(ii) Members of the Incumbent Board cease for any reason to constitute at least a majority of the Board; or 

(iii) Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of
the Company or an acquisition of assets of another entity (a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial
owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding
shares of common equity and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors or other similar governing body, as the case may be, of the entity resulting from such Business
Combination (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same
proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any employee benefit plan (or related
trust) of the Company or the entity resulting from such Business Combination) beneficially owns, directly or indirectly, 40% or more of, respectively, the then outstanding shares of common equity of the entity resulting from such Business
Combination or the combined voting power of the then outstanding voting securities of 

  
 2 

 
such entity except to the extent that such ownership results solely from ownership of the Company that existed prior to the Business Combination and (C) at least a majority of the members of
the board of directors or other similar governing body of the entity resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for
such Business Combination; or 
 (iv) Approval by the stockholders of the Company of a complete liquidation or dissolution of the
Company. 
 “Claim” means an actual or threatened claim or request for relief which was, is or may be made by reason of anything
done or not done by Indemnitee in, or by reason of any event or occurrence related to, Indemnitee’s Corporate Status, including any threatened, pending or completed action, suit, arbitration, investigation, inquiry, alternate dispute resolution
mechanism, administrative or legislative hearing, or any other proceeding (including, without limitation, any securities laws action, suit, arbitration, alternative dispute resolution mechanism, hearing, or procedure) whether civil, criminal,
administrative, arbitrative or investigative and whether or not based upon events occurring, or actions taken, before the date hereof, and any appeal in or related to any such action, suit, arbitration, investigation, hearing or procedure and any
inquiry or investigation (including discovery), whether conducted by or in the right of the Company or any other Person, that Indemnitee in good faith believes could lead to any such action, suit, arbitration, alternative dispute resolution
mechanism, hearing or other proceeding or appeal thereof. 
 “Corporate Status” means the status of a person who is, becomes or
was a director, officer, employee, agent or fiduciary of the Company or is, becomes or was serving at the request of the Company as a director, officer, partner, member, venturer, proprietor, trustee, employee, agent, fiduciary or similar
functionary of another foreign or domestic corporation, partnership, limited liability company, joint venture, sole proprietorship, trust, employee benefit plan or other enterprise. For purposes of this Agreement, the Company agrees that
Indemnitee’s service on behalf of or with respect to any Subsidiary of the Company shall be deemed to be at the request of the Company. 

“DGCL” means the Delaware General Corporation Law and any successor statute thereto, as either of them may from time to time be
amended. 
 “Disinterested Director” with respect to any request by Indemnitee for indemnification hereunder, means a director of
the Company who at the time of the vote is not a named defendant or respondent in the Claim in respect of which indemnification is sought by Indemnitee. 

“Exchange Act” means the Securities Exchange Act of 1934. 

“Expenses” means all attorneys’ fees and disbursements, retainers, accountant’s fees and disbursements, private
investigator fees and disbursements, court costs, transcript costs, fees and expenses of experts, witness fees and expenses, costs and obligations under any bond posted in 

  
 3 

 
connection with any Claim, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements, costs or expenses of the
types customarily incurred in connection with prosecuting, defending (including affirmative defenses and counterclaims), preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in or
preparing to participate in (including on appeal) a Claim and all interest or finance charges attributable to any thereof. Should any payments by the Company under this Agreement be determined to be subject to any federal, state or local income or
excise tax, “Expenses” shall also include such amounts as are necessary to place Indemnitee in the same after-tax position (after giving effect to all applicable taxes) as Indemnitee would have been
in had no such tax been determined to apply to such payments. Also, in this Agreement “witness” includes responding (or objecting) to a discovery request, whether in writing or in an oral deposition, in any Claim. 

“Final Adjudication” means a final adjudication by a court from which there is no further right of appeal or a final adjudication of
an arbitration pursuant to Section 5.1 if Indemnitee elects to seek such arbitration. 
 “Incumbent Board” means the
individuals who, as of the date of this Agreement, constitute the Board and any other individual who becomes a director of the Company after that date and whose election or appointment by the Board or nomination for election by the Company’s
stockholders was approved by a vote of at least a majority of the directors then comprising the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened
election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Incumbent Board. 

“Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither
contemporaneously is, nor in the five years theretofore has been, retained to represent: (a) the Company, any subsidiary of the Company, or Indemnitee in any matter material to either such Person (other than as Independent Counsel under this
Agreement or similar agreements), (b) any other party to the Claim giving rise to a claim for indemnification hereunder or (c) the beneficial owner, directly or indirectly, of securities of the Company representing 5% or more of the
combined voting power of the Company’s then outstanding voting securities, or Person controlled by such beneficial owner (other than, in each such case under clauses (a) through (c)), with respect to matters concerning the rights of
Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements). Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of
professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. 

“Independent Directors” means the directors on the Board that are independent directors as defined in NASDAQ Marketplace Rule
4200(a)(15) or successor provision, or, if the Company’s Common Stock is not then quoted on the NASDAQ Global Select Market, that qualify as independent, disinterested, or a similar term as defined in the rules of the principal securities
exchange or inter-dealer quotation system on which the Company’s Common Stock is then listed or quoted. 

  
 4 

 “Person” means any individual, entity or group (within the meaning of Sections 13(d)(3)
and 14(d)(2) of the Exchange Act). 
 “Potential Change in Control” shall be deemed to have occurred if (i) any Person shall
have announced publicly an intention to effect a Change in Control, or commenced any action (such as the commencement of a tender offer for the Company’s Outstanding Company Common Stock or Outstanding Company Voting Securities or the
solicitation of proxies for the election of any of the Company’s directors) that, if successful, could reasonably be expected to result in the occurrence of a Change in Control; (ii) the Company enters into an agreement, the consummation
of which would constitute a Change in Control; or (iii) any other event occurs which the Board declares to be a Potential Change of Control. 

“Subsidiary” means, with respect to any Person, any corporation or other entity of which a majority of the voting power of the
voting equity securities or equity interest is owned, directly or indirectly, by that Person. 
 “Voting Securities” means any
securities that vote generally in the election of directors, in the admission of general partners, or in the selection of any other similar governing body. 

ARTICLE II 
 Services by
Indemnitee 
 Indemnitee is serving as a director and officer of the Company. Indemnitee may from time to time also agree to serve, as
the Company may request from time to time, in another capacity for the Company (including another officer or director position) or as a director, officer, partner, member, venturer, proprietor, trustee, employee, agent, fiduciary or similar
functionary of another foreign or domestic corporation, partnership, joint venture, limited liability company, sole proprietorship, trust, employee benefit plan or other enterprise. Indemnitee and the Company each acknowledge that they have entered
into this Agreement as a means of inducing Indemnitee to serve, or continue to serve, the Company in such capacities. Indemnitee may at any time and for any reason resign from such position or positions (subject to any other contractual obligation
or any obligation imposed by operation of law). The Company shall have no obligation under this Agreement to continue Indemnitee in any such position or positions. 

ARTICLE III 

Indemnification 

Section 3.1 General. Subject to the provisions set forth in Article IV, the Company shall indemnify, and advance Expenses to,
Indemnitee to the fullest extent permitted by applicable law in effect on the date hereof and to such greater extent as applicable law may hereafter from time to time permit. The other provisions set forth in this Agreement are provided in addition
to and 

  
 5 

 
as a means of furtherance and implementation of, and not in limitation of, the obligations expressed in this Article III. No requirement, condition to or limitation of any right to
indemnification or to advancement of Expenses under this Article III shall in any way limit the rights of Indemnitee under Article VII. 

Section 3.2 Additional Indemnity of the Company. Indemnitee shall be entitled to indemnification pursuant to this Section 3.2
if, by reason of anything done or not done by Indemnitee in, or by reason of any event or occurrence related to, Indemnitee’s Corporate Status, Indemnitee is, was or becomes, or is threatened to be made, a party to, or witness or other
participant in any Claim. Pursuant to this Section 3.2, Indemnitee shall be indemnified against any and all Expenses, judgments, penalties (including excise or similar taxes), fines and amounts paid in settlement (including all interest,
assessments and other charges paid or payable in connection with or in respect of any such Expenses, judgments, penalties, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in
connection with such Claim, issue or matter therein. Notwithstanding the foregoing, the obligations of the Company under this Section 3.2 shall be subject to the condition that no determination (which, in any case in which Independent Counsel
is involved, shall be in a form of a written opinion) shall have been made pursuant to Article IV that Indemnitee would not be permitted to be indemnified under applicable law. Nothing in this Section 3.2 shall limit the benefits of
Section 3.1, Section 3.3 or any other Section hereunder. 
 Section 3.3 Advancement of Expenses. The Company shall
pay, on a current and as-incurred basis, all Expenses reasonably incurred by, or in the case of retainers to be incurred by, or on behalf of Indemnitee (or, if applicable, reimburse Indemnitee for any and all Expenses reasonably incurred by
Indemnitee and previously paid by Indemnitee) in connection with any Claim, whether brought by the Company or otherwise, in advance of the later of (a) the final, non-appealable determination or resolution of all such Claims and (b) any
determination respecting entitlement to indemnification pursuant to Article IV hereof (and shall continue to pay such Expenses after such determination and until it shall ultimately be determined (in a Final Adjudication) that Indemnitee is not
entitled to be indemnified by the Company against such Expenses). Such payments and advances shall be made within 10 days after the receipt by the Company of a written request from Indemnitee requesting such payment or payments from time to time,
whether prior to or after the final, non-appealable determination or resolution of such Claim. Any such payment by the Company is referred to in this Agreement as an “Expense Advance.” Any dispute as to the reasonableness of the incurrence
of any Expense shall not delay an Expense Advance by the Company, and the Company agrees that any such dispute shall be resolved only upon the final, non-appealable determination or resolution of the respective underlying Claim involving Indemnitee.
Indemnitee hereby undertakes and agrees that Indemnitee will reimburse and repay the Company without interest for any Expense Advances to the extent that it shall ultimately be determined (in a Final Adjudication) that Indemnitee is not entitled
under the law to be indemnified by the Company against such Expenses. Indemnitee shall not be required to provide collateral or otherwise secure the undertaking and agreement described in the prior sentence. The Company shall make all Expense
Advances pursuant to this Section 3.3 without regard to the financial ability of the Indemnitee to make repayment and without regard to whether or not the Indemnitee may ultimately be found to be entitled to indemnification under the provisions
of this Agreement. 

  
 6 

 Section 3.4 Indemnification for Additional Expenses. The Company shall indemnify
Indemnitee against any and all costs and expenses (of the types described in the definition of Expenses in Article I) and, if requested by Indemnitee, shall (within two business days of that request) advance those costs and expenses to Indemnitee,
that are incurred by Indemnitee in connection with any claim asserted against, or action brought by, Indemnitee for (i) indemnification or an Expense Advance by the Company under this Agreement or any other agreement or provision of the
Company’s Certificate of Incorporation or Bylaws now or hereafter in effect relating to any Claim, (ii) recovery under any directors’ and officers’ liability insurance policies maintained by the Company, or (iii) enforcement
of, or claims for breaches of, any provision of this Agreement, in each of the foregoing situations regardless of whether Indemnitee ultimately is determined to be entitled to that indemnification, Expense Advance payment, insurance recovery,
enforcement, or damage claim, as the case may be, and regardless of whether the nature of the proceeding with respect to such matters is judicial, by arbitration, or otherwise. 

Section 3.5 Partial Indemnity. If Indemnitee is entitled under any provision of this Agreement to indemnification by the
Company for some or a portion of the Expenses, judgments, fines, penalties, and amounts paid in settlement of a Claim but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof
to which Indemnitee is entitled. Moreover, notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in defense of any or all Claims, or in defense of any issue or matter
therein, including dismissal without prejudice, Indemnitee shall be indemnified against all Expenses incurred in connection therewith. 

ARTICLE IV
 Procedure for
Determination of Entitlement to Indemnification 
 Section 4.1 Request by Indemnitee. To obtain indemnification under
this Agreement, Indemnitee shall, at such time as determined by Indemnitee in Indemnitee’s sole discretion, submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to
Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary or an Assistant Secretary of the Company shall, promptly upon receipt of such a request for indemnification,
advise the Board in writing that Indemnitee has requested indemnification. Nevertheless, any failure of Indemnitee to provide a request to the Company, or to provide such a requestwithin any time frame, shall not relieve the Company of any liability
that it may have to Indemnitee hereunder. 
 Section 4.2 Determination of Request. Upon written request by Indemnitee for
indemnification pursuant to the first sentence of Section 4.1 hereof, a determination, if required by applicable law, with respect to whether Indemnitee is permitted under applicable law to be 

  
 7 

 
indemnified shall be made in accordance with the terms of Section 4.5, in the specific case as set forth in this Section 4.2: 

(a) If a Potential Change in Control or a Change in Control shall have occurred, by Independent Counsel (selected in
accordance with Section 4.3) in a written opinion to the Board and Indemnitee, unless Indemnitee shall request that such determination be made by the Board, or a committee of the Board, in which case by the person or persons or in the manner
provided for in clause (i) or (ii) of paragraph (b) below; or 
 (b) If a Potential Change in Control or
a Change in Control shall not have occurred, then the determination shall be made by one of the following, in Indemnitee’s sole discretion, as the Indemnitee requests in writing: (i) by the Board by a majority vote of the Disinterested
Directors even though less than a quorum of the Board, or (ii) by a majority vote of a committee solely of two or more Disinterested Directors designated to act in the matter by a majority vote of all Disinterested Directors even though less
than a quorum of the Board, or (iii) by Independent Counsel selected by the Board or a committee of the Board by a vote as set forth in clauses (i) or (ii) of this paragraph (b), or if such vote is not obtainable or such a committee
cannot be established, by a majority vote of all directors, or (iv) by the stockholders of the Company in a vote that excludes the shares held by directors who are not Disinterested Directors. 

If it is so determined that Indemnitee is permitted to be indemnified under applicable law, payment to Indemnitee shall be made within 10 days after such
determination. Nothing contained in this Agreement shall require that any determination be made under this Section 4.2 prior to the final, non-appealable determination or resolution of a Claim involving Indemnitee for which indemnification is
sought hereunder; provided, that Expense Advances shall continue to be made by the Company pursuant to, and to the extent required by, the provisions of Article III. Indemnitee shall cooperate with the person or persons making such determination
with respect to Indemnitee’s entitlement to indemnification, including providing to such person upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is
reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person or persons making such determination
shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification), and the Company shall indemnify and hold harmless Indemnitee therefrom. 

Section 4.3 Independent Counsel. If the determination of entitlement to indemnification is to be made by Independent Counsel, the
Independent Counsel shall be selected by Indemnitee, and Indemnitee shall give written notice to the Company, within 10 days after submission of Indemnitee’s request for indemnification, specifying the identity and address of the Independent
Counsel so selected unless Indemnitee shall request that such selection be made by the Disinterested Directors or a committee of the Board, in which event the Company shall give written notice to Indemnitee within 10 days after receipt of
Indemnitee’s request for the Board or a committee of the Disinterested Directors to make such selection, specifying the identity and address of the Independent Counsel so selected. In either event, (i) such notice to Indemnitee or

  
 8 

 
the Company, as the case may be, shall be accompanied by a written confirmation by the Independent Counsel so selected that it satisfies the requirements of the definition of “Independent
Counsel” in Article I and that it agrees to serve in such capacity and (ii) Indemnitee or the Company, as the case may be, may, within seven days after such written notice of selection shall have been given, deliver to the Company or to
Indemnitee, as the case may be, a written objection to such selection. Any objection to the selection of Independent Counsel pursuant to this Section 4.3 may be asserted only on the ground that the Independent Counsel so selected does not meet
the requirements of the definition of “Independent Counsel” in Article I, and the objection shall set forth with particularity the factual basis of such assertion. If such written objection is timely made, the Independent Counsel so
selected may not serve as Independent Counsel unless and until a court of competent jurisdiction (the “Court”) has determined that such objection is without merit or such objection is withdrawn. In the event of a timely written objection
to a choice of Independent Counsel, the party originally selecting the Independent Counsel shall have seven days to make an alternate selection of Independent Counsel and to give written notice of such selection to the other party, after which time
such other party shall have five days to make a written objection to such alternate selection. If, within 30 days after submission of Indemnitee’s request for indemnification pursuant to Section 4.1, no Independent Counsel shall have been
selected and not objected to, either the Company or Indemnitee may petition the Court for resolution of any objection that shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the
appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom an objection is so resolved or the person so appointed shall act as Independent Counsel
under Section 4.2. The Company shall pay any and all fees and expenses reasonably incurred by, such Independent Counsel in connection with acting pursuant to Section 4.2, and the Company shall pay all fees and expenses reasonably incurred
incident to the procedures of this Section 4.3, regardless of the manner in which such Independent Counsel was selected or appointed. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 5.1, Independent
Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

Section 4.4 Establishment of a Trust. In the event of a Potential Change in Control or a Change in Control, the Company shall,
upon written request by Indemnitee, create a trust for the benefit of Indemnitee (the “Trust”) and from time to time upon written request of Indemnitee shall fund the Trust in an amount sufficient to satisfy any and all Expenses reasonably
anticipated at the time of each such request to be incurred in connection with investigating, preparing for, and defending any Claim, and any and all judgments, fines, penalties, and settlement amounts of any and all Claims from time to time
actually paid or claimed, reasonably anticipated, or proposed to be paid. The amount to be deposited in the Trust pursuant to the foregoing funding obligation shall be determined by the Independent Counsel (or other person(s) making the
determination of whether Indemnitee is permitted to be indemnified by applicable law). The terms of the Trust shall provide that, upon a Change in Control, (i) the Trust shall not be revoked or the principal thereof invaded, without the written
consent of Indemnitee; (ii) the trustee of the Trust shall advance to Indemnitee, within ten days of a request by Indemnitee, any and all Expenses reasonably incurred by, or in case of retainer to be incurred by, or on behalf of

  
 9 

 
Indemnitee (or, if applicable, reimburse Indemnitee for any Expense reasonably incurred by Indemnitee and previously paid by Indemnitee), with any required determination concerning the
reasonableness of the Expenses to be made by the Independent Counsel (and Indemnitee hereby agrees to reimburse the Trust under the circumstances in which Indemnitee would be required to reimburse the Company for Expense Advances under
Section 3.3 of this Agreement); (iii) the Trust shall continue to be funded by the Company in accordance with the funding obligation set forth above; (iv) the trustee of the Trust shall promptly pay to Indemnitee all amounts for which
Indemnitee shall be entitled to indemnification pursuant to this Agreement; and (v) all unexpended funds in the Trust shall revert to the Company upon a final determination by the Independent Counsel or a Final Adjudication, as the case may be,
that Indemnitee has been fully indemnified under the terms of this Agreement. The trustee of the Trust shall be chosen by Indemnitee and shall be an institution that is not affiliated with Indemnitee. Nothing in this Section 4.4 shall relieve
the Company of any of its obligations under this Agreement. 
 Section 4.5 Presumptions and Effect of Certain Proceedings. 

(a) Indemnitee shall be presumed to be entitled to indemnification under this Agreement upon submission of a request for
indemnification under Section 4.1, and the Company shall have the burden of proof in overcoming that presumption in reaching a determination contrary to that presumption. Such presumption shall be used by Independent Counsel (or other person or
persons determining entitlement to indemnification) as a basis for a determination of entitlement to indemnification unless the Company provides information sufficient to overcome such presumption by clear and convincing evidence or unless the
investigation, review and analysis of Independent Counsel (or such other person or persons) convinces Independent Counsel by clear and convincing evidence that the presumption should not apply. 

(b) If the person or persons empowered or selected under Article IV of this Agreement to determine whether Indemnitee is
entitled to indemnification shall not have made a determination within 60 days after receipt by the Company of the request by Indemnitee therefor, the determination of entitlement to indemnification shall be deemed to have been made and Indemnitee
shall be entitled to such indemnification; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional 30 days, if the person making the determination with respect to entitlement to indemnification
in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating to such determination; and provided, further, that the 60-day limitation set forth in this Section 4.5(b) shall not apply
and such period shall be extended as necessary (i) if within 30 days after receipt by the Company of the request for indemnification under Section 4.1 Indemnitee and the Company have agreed, and the Board has resolved, to submit such
determination to the stockholders of the Company pursuant to Section 4.2(b) for their consideration at an annual meeting of stockholders to be held within 90 days after such agreement and such determination is made thereat, or a special meeting
of stockholders is called within 30 days after such receipt for the purpose of making such determination, such meeting is held for such purpose within 60 days after having been so called and such determination

  
 10 

 
is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 4.2(a) of this Agreement, in which case the
applicable period shall be as set forth in Section 5.1(c). 
 (c) The termination of any Claim, issue or matter by
judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) by itself adversely affect the rights of
Indemnitee to indemnification or create a presumption that Indemnitee failed to meet any particular standard of conduct, that Indemnitee had any particular belief, or that a court has determined that indemnification is not permitted by applicable
law. Indemnitee may be found to have failed to meet any particular standard of conduct in respect of any Claim, issue or matter only after Indemnitee shall have been so adjudged by the Court or arbitrator, as applicable, after exhaustion of all
appeals therefrom. 
 (d) For purposes of the second sentence of Section 3.5, a settlement or other resolution of a
Claim short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty. For purposes of the second sentence of Section 3.5, in the event that any Claim to which Indemnitee is a
party is resolved in any manner other than by adverse judgment against Indemnitee (including settlement of such Claim with or without payment of money or other consideration), it shall be presumed that Indemnitee has been successful on the merits or
otherwise in suchClaim. Anyone seeking to overcome this presumption shall have the burden of proof by clear and convincing evidence. 

(e) The failure of the Company (including by its directors or Independent Counsel) to have made a determination before the
commencement of any action pursuant to this Agreement that indemnification is proper because Indemnitee has met the applicable standard of conduct shall not be a defense to the action or create a presumption that Indemnitee has not met the standard
of conduct. 
 ARTICLE V 

Certain Remedies of Indemnitee 

Section 5.1 Indemnitee Entitled to Adjudication in an Appropriate Court. If (a) a determination is made pursuant to Article
IV that Indemnitee is not entitled to indemnification under this Agreement; (b) there has been any failure by the Company to make timely payment or advancement of any amounts due hereunder (including, without limitation, any Expense Advances);
or (c) the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 4.2 and such determination shall not have been made and delivered in a written opinion within 60 days after the latest of
(i) such Independent Counsel’s being appointed, (ii) the overruling by the Court of objections to such counsel’s selection, or (iii) expiration of all periods for the Company or Indemnitee to object to such counsel’s
selection, Indemnitee shall be entitled to commence an action seeking an adjudication in the Court of Indemnitee’s entitlement to such indemnification or advancements due hereunder, 

  
 11 

 
including, without limitation, Expense Advances. Alternatively, Indemnitee, in Indemnitee’s sole discretion, may seek an award in arbitration to be conducted by a single arbitrator pursuant
to the commercial arbitration rules of the American Arbitration Association. Indemnitee shall commence such action seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to
commence such action pursuant to this Section 5.1, or such right shall expire. The Company agrees not to oppose Indemnitee’s right to seek any such adjudication or award in arbitration and it shall continue to pay Expense Advances pursuant
to Section 3.3 until it shall ultimately be determined (in a Final Adjudication) that Indemnitee is not entitled to be indemnified by the Company against such Expenses. 

Section 5.2 Adverse Determination Not to Affect any Judicial Proceeding. If a determination shall have been made pursuant to
Article IV that Indemnitee is not entitled to indemnification under this Agreement, any judicial proceeding or arbitration commenced pursuant to this Article V shall be conducted in all respects as a de novo trial or arbitration on the merits, and
Indemnitee shall not be prejudiced by reason of such initial adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Article V, Indemnitee shall be presumed to be entitled to indemnification or advancement of
Expenses, as the case may be, under this Agreement and the Company shall have the burden of proof in overcoming such presumption and to show by clear and convincing evidence that Indemnitee is not entitled to indemnification or advancement of
Expenses, as the case may be. 
 Section 5.3 Company Bound by Determination Favorable to Indemnitee in any Judicial Proceeding or
Arbitration. If a determination shall have been made or deemed to have been made pursuant to Article IV that Indemnitee is entitled to indemnification, the Company shall be irrevocably bound by such determination in any judicial proceeding or
arbitration commenced pursuant to this Article V, and shall be precluded from asserting that such determination has not been made or that the procedure by which such determination was made is not valid, binding and enforceable. 

Section 5.4 Company Bound by the Agreement. The Company shall be precluded from asserting in any judicial proceeding or
arbitration commenced pursuant to this Article V that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the
provisions of this Agreement. Without limiting the generality of the preceding sentence, the Company shall not seek from a court, or agree to, a “bar order” that would have the effect of prohibiting or limiting Indemnitee’s rights to
advancement of any Expenses under this Agreement. 
 ARTICLE VI 

Contribution 

Section 6.1 Contribution Payment. 

(a) Whether or not the indemnification provided in Article III hereof is available, in respect of any threatened, pending
or completed action, suit or Claim in which the 

  
 12 

 
Company is jointly liable with Indemnitee (or would be if joined in such action, or Claim), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such
action, suit or Claim without requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any action,
suit or Claim in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit orClaim) unless such settlement provides for a full and final release of all claims asserted against Indemnitee. 

(b) Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any
reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or Claim in which the Company is jointly liable with Indemnitee (or would be if joined in such
action, suit orClaim), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the
Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit orClaim), on the one hand, and Indemnitee, on the other hand, from the
transaction or events from which such action, suit or Claim arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative
fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit orClaim), on the one hand, and Indemnitee, on the other hand, in
connection with the transaction or events that resulted in such Expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered. 

(c) The Company hereby agrees, to the fullest extent permitted by applicable law, to fully indemnify and hold Indemnitee
harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee. 

(d) To the fullest extent permissible under applicable law and without diminishing or impairing the obligations of the
Company set forth in the preceding subparagraphs of this Section 6.1, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall
contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this
Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Claim in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or
transaction(s) giving cause to suchClaim; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). 

  
 13 

 Section 6.2 Relative Fault. The relative fault of the Indemnitee, on the one hand,
and of the Company and any and all other parties (including officers and directors of the Company other than Indemnitee) who may be at fault with respect to such matter shall be determined (i) by reference to the relative fault of Indemnitee as
determined by the court or other governmental agency assessing the contribution amounts or (ii) to the extent such court or other governmental agency does not apportion relative fault, by the Independent Counsel (or such other party which makes
a determination under Article IV) after giving effect to, among other things, the degree of which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary, the degree to
which their conduct is active or passive, the degree of the knowledge, access to information, and opportunity to prevent or correct the subject matter of the Claims and other relevant equitable considerations of each party. The Company and
Indemnitee agree that it would not be just and equitable if contribution pursuant to this Section 6.2 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to in this Section 6.2. 
 ARTICLE VII 

Miscellaneous 

Section 7.1 Non-Exclusivity. The rights of Indemnitee to receive indemnification and advancement of Expenses under this Agreement
shall be in addition to, and shall not be deemed exclusive of, any other rights Indemnitee shall under the DGCL or other applicable law, the charter or bylaws of the Company, any other agreement, vote of stockholders or a resolution of directors, or
otherwise. Every other right or remedy of Indemnitee shall be cumulative of the rights and remedies granted Indemnitee hereunder. No amendment or alteration of the charter or bylaws of the Company or any provision thereof shall adversely affect
Indemnitee’s rights hereunder, and such rights shall be in addition to any rights Indemnitee may have under the charter, bylaws and the DGCL or other applicable law. To the extent that there is a change in the DGCL or other applicable law
(whether by statute or judicial decision) that allows greater indemnification by agreement than would be afforded currently under the Company’s charter or bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall
enjoy by virtue of this Agreement the greater benefit so afforded by such change. Any amendment, alteration or repeal of the DGCL that adversely affects any right of Indemnitee shall be prospective only and shall not limit or eliminate any such
right with respect to any Claim involving any occurrence or alleged occurrence of any action or omission to act that took place before the effective date of such amendment or repeal. 

  
 14 

 Section 7.2 Insurance and Subrogation. 

(a) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors,
officers, employees, agents or fiduciaries of the Company or for individuals serving at the request of the Company as directors, officers, partners, members, venturers, proprietors, trustees, employees, agents, fiduciaries or similar functionaries
of another foreign or domestic corporation, partnership, limited liability company, joint venture, sole proprietorship, trust, employee benefit plan or other enterprise, Indemnitee shall be covered by such policy or policies in accordance with its
or their terms to the maximum extent of the coverage available for any such director, officer, employee, agent or fiduciary under such policy or policies. 

(b) In the event of any payment by the Company under this Agreement for which reimbursement is available under any
insurance policy or policies obtained by the Company, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee under such insurance policy or policies, who shall execute all papers required and
take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights, provided that all Expenses relating to such action shall be borne by the Company.

 (c) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable
hereunder if and to the extent that Indemnitee has otherwise actually received such payment under the Company’s charter or bylaws or any insurance policy, contract, agreement or otherwise. 

(d) If Indemnitee is a director of the Company, the Company will advise the Board of any proposed material reduction in
the coverage for Indemnitee to be provided by the Company’s directors’ and officers’ liability insurance policy and will not effect such a reduction with respect to Indemnitee without the prior approval of at least 80% of the
Independent Directors of the Company. 
 (e) If Indemnitee is a director of the Company during the term of this
Agreement and if Indemnitee ceases to be a director of the Company for any reason, the Company shall procure a run-off directors’ and officers’ liability insurance policy with respect to claims arising from facts or events that occurred
before the time Indemnitee ceased to be a director of the Company and covering Indemnitee, which policy, without any lapse in coverage, will provide coverage for a period of six years after the time Indemnitee ceased to be a director of the Company
and will provide coverage (including amount and type of coverage and size of deductibles) that are substantially comparable to the Company’s directors’ and officers’ liability insurance policy that was most protective of Indemnitee in
the 12 months preceding the time Indemnitee ceased to be a director of the Company and that is reasonably satisfactory to Indemnitee; provided, however, that: 

(i) this obligation shall be suspended during the period immediately following the time Indemnitee ceases to be a director
of the Company if and only so long as the Company has a directors’ and officers’ liability insurance policy in 

  
 15 

 
effect covering Indemnitee for such claims that, if it were a run-off policy, would meet or exceed the foregoing standards, but in any event this suspension period shall end when a Change in
Control occurs; and 
 (ii) no later than the end of the suspension period provided in the preceding clause
(i) (whether because of failure to have a policy meeting the foregoing standards or because a Change in Control occurs), the Company shall procure a run-off directors’ and officers’ liability insurance policy meeting the foregoing
standards and lasting for the remainder of the six-year period. 

(f) Notwithstanding the preceding clause (e) including the suspension provisions therein, if Indemnitee ceases to be
an officer or a director of the Company in connection with a Change in Control or at or during the one-year period following the occurrence of a Change in Control, the Company shall procure a run-off directors’ and officers’ liability
insurance policy covering Indemnitee that is reasonably satisfactory to Indemnity, meets the foregoing standards in clause (e), and lasts for a six-year period upon the Indemnitee’s ceasing to be an
officer or a director of the Company in such circumstances. 
 (g) If at the time of the receipt of a notice of a Claim
pursuant to the terms hereof, the Company has directors’ and officers’ liability insurance in effect, the Company shall give prompt notice of the commencement of such Claim to the insurers in accordance with the procedures set forth in the
respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Claim in accordance with the terms of such policies. 

Section 7.3 Self Insurance of the Company; Other Arrangements. The parties hereto recognize that the Company may, but except as
provided in Section 7.2(d), Section 7.2(e), and Section 7.2(f) is not required to, procure or maintain insurance or other similar arrangements, at its expense, to protect itself and any person, including Indemnitee, who is or was a
director, officer, employee, agent or fiduciary of the Company or who is or was serving at the request of the Company as a director, officer, partner, member, venturer, proprietor, trustee, employee, agent, fiduciary or similar functionary of
another foreign or domestic corporation, partnership, limited liability company, joint venture, sole proprietorship, trust, employee benefit plan or other enterprise against any expense, liability or loss asserted against or incurred by such person,
in such a capacity or arising out of the person’s status as such a person, whether or not the Company would have the power to indemnify such person against such expense or liability or loss. 

Except as provided in Section 7.2(d), Section 7.2(e) and Section 7.2(f), in considering the cost and availability of such
insurance, the Company (through the exercise of the business judgment of its directors and officers) may, from time to time, purchase insurance which provides for certain (i) deductibles, (ii) limits on payments required to be made by the
insurer, or (iii) coverage which may not be as comprehensive as that previously included in insurance purchased by the Company or its predecessors. The purchase of insurance with deductibles, limits on payments and coverage exclusions, even if
in the best interest of the Company, may not 

  
 16 

 
be in the best interest of Indemnitee. As to the Company, purchasing insurance with deductibles, limits on payments and coverage exclusions is similar to the Company’s practice of
self-insurance in other areas. In order to protect Indemnitee who would otherwise be more fully or entirely covered under such policies, the Company shall, to the maximum extent permitted by applicable law, indemnify and hold Indemnitee harmless to
the extent (i) of such deductibles, (ii) of amounts exceeding payments required to be made by an insurer, or (iii) of amounts that prior policies of directors’ and officers’ liability insurance held by the Company or its
predecessors have provided for payment to Indemnitee, if by reason of Indemnitee’s Corporate Status Indemnitee is or is threatened to be made a party to anyClaim. The obligation of the Company in the preceding sentence shall be without regard
to whether the Company would otherwise be required to indemnify such officer or director under the other provisions of this Agreement, or under any law, agreement, vote of stockholders or directors or other arrangement. Without limiting the
generality of any provision of this Agreement, the procedures in Article IV hereof shall, to the extent applicable, be used for determining entitlement to indemnification under this Section 7.3. 

Section 7.4 Certain Settlement Provisions. The Company shall have no obligation to indemnify Indemnitee under this Agreement for
amounts paid in settlement of a Claim without the Company’s prior written consent. The Company shall not settle any Claim in any manner that would impose any fine or other obligation on Indemnitee without Indemnitee’s prior written
consent. Neither the Company nor Indemnitee shall unreasonably withhold their consent to any proposed settlement. 
 Section 7.5
Duration of Agreement. This Agreement shall continue for so long as Indemnitee serves as a director, officer, employee, agent or fiduciary of the Company or, at the request of the Company, as a director, officer, partner, member, venturer,
proprietor, trustee, employee, agent, fiduciary or similar functionary of another foreign or domestic corporation, partnership, limited liability company, joint venture, sole proprietorship, trust, employee benefit plan or other enterprise, and
thereafter shall survive until and terminate upon the later to occur of: (a) the expiration of 20 years after the latest date that Indemnitee shall have ceased to serve in any such capacity; (b) the final non-appealable determination or
resolution of all pending Claims in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Article IV relating thereto; or (c) the
expiration of all statutes of limitation applicable to possible Claims arising out of Indemnitee’s Corporate Status. 

Section 7.6 Notice by Each Party. Indemnitee shall promptly notify the Company in writing upon being served with any summons,
citation, subpoena, complaint, indictment, information or other document or communication relating to any Claim for which Indemnitee may be entitled to indemnification or advancement of Expenses hereunder; provided, however, that any failure of
Indemnitee to so notify the Company shall not adversely affect Indemnitee’s rights under this Agreement except to the extent the Company shall have been materially prejudiced as a direct result of such failure. The Company shall promptly notify
Indemnitee in writing as to the pendency of any Claim that may involve a claim against Indemnitee for which Indemnitee may be entitled to indemnification or advancement of Expenses hereunder. 

  
 17 

 Section 7.7 Amendment. This Agreement may not be modified or amended except by a
written instrument executed by or on behalf of each of the parties hereto. 
 Section 7.8 Waivers. The observance of any term of
this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) by the party entitled to enforce such term only by a writing signed by the party against which such waiver is to be asserted.
Unless otherwise expressly provided herein, no delay on the part of any party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party hereto of any right, power or
privilege hereunder operate as a waiver of any other right, power or privilege hereunder nor shall any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other
right, power or privilege hereunder. 
 Section 7.9 Entire Agreement. This Agreement and the documents expressly referred to
herein constitute the entire agreement between the parties hereto with respect to the matters covered hereby, and any other prior or contemporaneous oral or written understandings or agreements with respect to the matters covered hereby, including
without limitation any prior indemnification agreements, are expressly superseded by this Agreement. 
 Section 7.10
Severability. If any provision of this Agreement (including any provision within a single section, paragraph or sentence), or the application of such provision to any Person or circumstance, shall be judicially declared to be invalid,
unenforceable or void, such decision will not have the effect of invalidating or voiding the remainder of this Agreement or affect the application of such provision to other Persons or circumstances, it being the intent and agreement of the parties
that this Agreement shall be deemed amended by modifying such provision to the extent necessary to render it valid, legal and enforceable while preserving its intent, or if such modification is not possible, by substituting therefor another
provision that is valid, legal and enforceable and that achieves the same objective. Any such finding of invalidity or unenforceability shall not prevent the enforcement of such provision in any other jurisdiction to the maximum extent permitted by
applicable law. 
 Section 7.11 Notices. All notices and other communications hereunder shall be in writing and shall be deemed
given upon (a) transmitter’s confirmation of a receipt of a facsimile transmission if during normal business hours of the recipient, otherwise on the next business day, (b) confirmed delivery of a standard overnight courier or when
delivered by hand or (c) the expiration of five business days after the date mailed by certified or registered mail (return 

  
 18 

 
receipt requested), postage prepaid, to the parties at the following addresses (or at such other addresses for a party as shall be specified by like notice): 

If to the Company, to it at: 

Reata Pharmaceuticals, Inc. 

2801 Gateway Drive 
 Suite 150

 Irving, Texas 75063-2648 

Attn: Corporate Secretary 

Facsimile: 469-442-4740 
 If to
Indemnitee, to Indemnitee at: 
 4506 Watauga Road 

Dallas, TX 75209 
 or to such other address or to
such other individuals as any party shall have last designated by notice to the other parties. All notices and other communications given to any party in accordance with the provisions of this Agreement shall be deemed to have been given when
delivered or sent to the intended recipient thereof in accordance with and as provided in the provisions of this Section 7.11. 

Section 7.12 Governing Law. This Agreement and the legal relations among the parties shall, to the fullest extent permitted by
law, be governed by, and construed and enforced in accordance with , the laws of the State of Delaware without regard to its conflict of laws rule. 

Section 7.13 Submission to Jurisdiction. The Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any
action or proceeding arising out of or in connection with this Agreement (other than an arbitration provided for in Section 5.1) shall be brought only in the Court of Chancery of the State of Delaware (the “Delaware Court”), and not
in any other state or federal court in the United States of America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Delaware Court for the purposes of any action or proceeding arising out of or in
connection with this Agreement, (c) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought
in the Delaware Court has been brought in an improper or otherwise inconvenient forum. 
 Section 7.14 Certain Construction
Rules. 
 (a) The article and section headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. As used in this Agreement, unless otherwise provided to the contrary, (1) all references to days shall be deemed references to calendar days and (2) any reference

  
 19 

 
to a “Section” or “Article” shall be deemed to refer to a section or article of this Agreement. The words “hereof,” “herein” and “hereunder” and
words of similar import referring to this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement. Whenever the words “include,” “includes” or “including” are used in this
Agreement, they shall be deemed to be followed by the words “without limitation.” Unless otherwise specifically provided for herein, the term “or” shall not be deemed to be exclusive. Whenever the context may require, any pronoun
used in this Agreement shall include the corresponding masculine, feminine or neuter forms and the singular form of nouns, pronouns and verbs shall include the plural and vice versa. 

(b) For purposes of this Agreement, references to “other enterprises” shall include employee benefit plans;
references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee
or agent of the Company which imposes duties on, or involves services by, such director, nominee, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a
manner the person reasonably believed to be in the interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interest of the Company” for purposes of this
Agreement and the DGCL. 
 (c) In the event of a merger, consolidation or amalgamation of the Company with or into any
other entity, references to the “Company” shall include the entity surviving or resulting from the merger, consolidation or amalgamation as well as the Company, and Indemnitee shall stand in the same position under this Agreement with
respect to the surviving or resulting entity as Indemnitee would stand with respect to the Company if its existence had continued upon and after the merger, consolidation or amalgamation. 

Section 7.15 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an
original and all of which together shall be deemed to be one and the same instrument, notwithstanding that both parties are not signatories to the original or same counterpart. 

Section 7.16 Certain Persons Not Entitled to Indemnification. Notwithstanding any other provision of this Agreement (but subject
to Section 7.1), Indemnitee shall not be entitled to indemnification or advancement of Expenses pursuant to the terms of this Agreement with respect to any Claim, issue or matter therein, brought or made by Indemnitee against the Company,
except as specifically provided in Article III, Article IV or Section 7.3. In addition, the Company shall not be obligated pursuant to the terms of this Agreement: 

(a) To indemnify Indemnitee if (and to the extent that) a final, non-appealable decision by a court or arbitration body
having jurisdiction in the matter shall determine that such indemnification is not lawful; or 

  
 20 

 (b) To indemnify Indemnitee for the payment to the Company of profits
pursuant to Section 16(b) of the Exchange Act, or Expenses incurred by Indemnitee for Claims in connection with such payment under Section 16(b) of the Exchange Act. 

Section 7.17 Indemnification for Negligence, Gross Negligence, etc. Without limiting the generality of any other provision
hereunder, it is the express intent of this Agreement that Indemnitee be indemnified and Expenses be advanced regardless of Indemnitee’s acts of negligence, gross negligence, intentional or willful misconduct to the extent that indemnification
and advancement of Expenses is allowed pursuant to the terms of this Agreement and under applicable law. 
 Section 7.18 Mutual
Acknowledgments. Both the Company and Indemnitee acknowledge that, in certain instances, applicable law (including applicable federal law that may preempt or override applicable state law) or public policy may prohibit the Company from
indemnifying the directors, officers, employees, agents or fiduciaries of the Company under this Agreement or otherwise. For example, the Company and Indemnitee acknowledge that the U.S. Securities and Exchange Commission has taken the position that
indemnification of directors, officers and controlling Persons of the Company for liabilities arising under federal securities laws is against public policy and, therefore, unenforceable. Indemnitee understands and acknowledges that the Company has
undertaken or may be required in the future to undertake with the Securities and Exchange Commission to submit the question of indemnification to a court in certain circumstances for a determination of the Company’s right under public policy to
indemnify Indemnitee. In addition, the Company and Indemnitee acknowledge that federal law prohibits indemnifications for certain violations of the Employee Retirement Income Security Act of 1974, as amended. 

Section 7.19 Enforcement. The Company agrees that its execution of this Agreement shall constitute a stipulation by which it shall
be irrevocably bound in any court or arbitration in which a proceeding by Indemnitee for enforcement of Indemnitee’s rights hereunder shall have been commenced, continued or appealed, that its obligations set forth in this Agreement are unique
and special, and that failure of the Company to comply with the provisions of this Agreement will cause irreparable and irremediable injury to Indemnitee, for which a remedy at law will be inadequate. As a result, in addition to any other right or
remedy Indemnitee may have at law or in equity with respect to breach of this Agreement, Indemnitee shall be entitled to injunctive or mandatory relief directing specific performance by the Company of its obligations under this Agreement. The
Company agrees not to seek, and agrees to waive any requirement for the securing or posting of, a bond in connection with Indemnitee’s seeking or obtaining such relief. 

Section 7.20 Successors and Assigns. All of the terms and provisions of this Agreement shall be binding upon, shall inure to the
benefit of and shall be enforceable by the parties hereto and their respective successors, assigns, heirs, executors, administrators, legal representatives. 

Section 7.21 Period of Limitations. No legal action shall be brought and no cause of action shall be asserted by or on behalf of
the Company or any affiliate of the Company against 

  
 21 

 
Indemnitee or Indemnitee’s spouse, heirs, executors, or personal or legal representatives after the expiration of one year from the date of accrual of that cause of action, and any claim or
cause of action of the Company or its affiliate shall be extinguished and deemed released unless asserted by the timely filing of a legal action within that one-year period; provided, however, that for any claim based on Indemnitee’s breach of
fiduciary duties to the Company or its stockholders, the period set forth in the preceding sentence shall be three years instead of one year; and provided, further, that, if any shorter period of limitations is otherwise applicable to any such cause
of action, the shorter period shall govern. 
 [signatures on following page] 

  
 22 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered to be effective as of the
date first above written. 
  

			
	REATA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jason D. Wilson

	Name:	 	Jason D. Wilson
	Title:	 	Chief Financial Officer
	
	INDEMNITEE:
	
	 /s/ J. Warren Huff

	Name:	 	J. Warren Huff

  
 23 

 Exhibit 10.1a 

Schedule of Indemnification Agreements 

The following are a list of Indemnification Agreements between the Registrant and the persons listed below that are substantially identical to the
Indemnification Agreement by and between the Registrant and J. Warren Huff as set forth in Exhibit 10.12: 
  

	 	1.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and James E. Bass 

 

	 	2.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Elaine Castellanos 

 

	 	3.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Edmund H. Doherty 

 

	 	4.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Arthur W. Gibson III 

 

	 	5.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Robin M. Kral 

 

	 	6.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and R. Kent McGaughy, Jr. 

 

	 	7.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Colin J. Meyer, MD 

 

	 	8.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Jack B. Nielsen 

 

	 	9.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Joel W. Proksch 

 

	 	10.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Edward W. Rose III 

 

	 	11.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Dennis K. Stone, MD 

 

	 	12.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Melean Visnick 

 

	 	13.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and John A. Walling, Ph.D. 

 

	 	14.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Keith W. Ward, Ph.D. 

	 	15.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and William C. Wigley 

 

	 	16.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Jason D. Wilson 

 

	 	17.	Indemnification Agreement, dated effective as of September 23, 2015, by and between Reata Pharmaceuticals, Inc. and Michael D. Wortley

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]